Real-World effectiveness Following Treatment with Pegylated-Interferon Alpha-2a Compared with Alpha-2b, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3 after entering Thai National Drug List
Not Applicable
Completed
- Conditions
- Intention to treat analysis of SVR vs treatment failure according to treatment response at various time points during treatment.Chronic hepatitis C,genotype3,peg-interferon and ribavirin,treatment,Thailand
- Registration Number
- TCTR20200313004
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
Has the following rules
1. Age 18-65 years
2. Viral load (HCV-RNA) more than 5000 IU / ml
3. Only species 2 and 3
4. Enzyme levels (alanine aminotransferase = ALT) from 1.5 times or more
5. Pathology in the liver From the liver puncture Or transient elastography equal to F2
6. Must not be treated with pegylated interferon and ribavirin
7. No joint diseases such as AIDS, kidney failure, renal impairment
8. Disease must be under control.
9. If cirrhosis, must be cirrhosis with Child Pugh score A (5-6).
Exclusion Criteria
no
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of treatment 3 year Compiled from the medical records of patients with chronic hepatitis C virus in all 3 funds that hav
- Secondary Outcome Measures
Name Time Method N/A N/A N/A